Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01063179|
Recruitment Status : Completed
First Posted : February 5, 2010
Last Update Posted : September 6, 2017
|Condition or disease||Intervention/treatment||Phase|
|Multiple Myeloma||Drug: Bortezomib, Melphalan, Prednisone, Thalidomide Drug: Bortezomib, Melphalan, Prednisone||Phase 3|
This phase III study represents a prospective randomized open label multicenter trial to evaluate whether the combination of VELCADE, Melphalan, Prednisone and Thalidomide (V-MPT), as induction treatment for newly diagnosed elderly MM patients, improves outcomes compared to the combination VELCADE-MP.
Subjects will be randomized in a 1:1 allocation between:
Arm A: 250 patients: V-MPT treatment Arm B: 250 patients: V-MP treatment Patients excluded from randomization are to be registered in Arm C. Patients randomized in arm A (Thalidomide based) will be further enrolled in the sub-study about the DVT prophylaxis.
Patients will be evaluated at scheduled visits in up to 3 study periods: pre-treatment, treatment and long-term follow-up (LTFU).
Screening visits, performed at study entry. After providing written informed consent to participate in the study, patients will be evaluated for study eligibility After registration subjects will be randomized.
Subjects in Arm A will receive:
nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT)
- Maintenance therapy:
Thalidomide in combination with VELCADE
Subjects in Arm B will receive:
nine 5-week courses of VELCADE/Melphalan/Prednisone (V-MP)
- No maintenance therapy is scheduled At the end of induction treatment or at the time of discontinuation of all study drugs, all patients are to attend study center visits on an every 6 to 8-week basis, until development of confirmed Progressive Disease (PD)
- LTFU period:
After development of confirmed PD all patients are to be followed for survival every 3 months via telephone or office visit.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||511 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A PHASE III, MULTI-CENTER, RANDOMIZED OPEN LABEL STUDY OF VELCADE, MELPHALAN, PREDNISONE AND THALIDOMIDE (V-MPT) Versus VELCADE, MELPHALAN, PREDNISONE (V-MP) IN ELDERLY UNTREATED MULTIPLE MYELOMA PATIENTS|
|Study Start Date :||May 2006|
|Actual Primary Completion Date :||July 2014|
|Actual Study Completion Date :||July 2014|
Experimental: Arm A: VMPT
Induction therapy with nine 5-week courses of VELCADE/Melphalan/Prednisone/Thalidomide (V-MPT) followed by maintenance therapy with Thalidomide and VELCADE
Drug: Bortezomib, Melphalan, Prednisone, Thalidomide
9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.
Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years.
Active Comparator: VMP
Induction therapy with nine 5-week courses of either VELCADE/Melphalan/Prednisone (V-MP).
No maintenance is scheduled.
Drug: Bortezomib, Melphalan, Prednisone
Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
- Determine whether the V-MPT combination improves progression free survival (PFS) [ Time Frame: Approximately 24 months ]
- Determine whether the VMPT combination improves:Response rate, Overall Survival rate, Time and duration of response, Assess the safety, Assess the prognostic factors [ Time Frame: Approximately 24 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01063179
|A.O.U. S. Giovanni Battista|
|Torino, Italy, 10126|
|Principal Investigator:||Mario Boccadoro, MD||Divisione di Ematologia dell'Università di Torino, A.O.U. S. Giovanni Battista, Torino;Italy|